

Pathophysiology II

Chapter (6): Cancer


- Cell cycle
- Cancer terminology
- Benign and malignant tumors
- Characteristics of malignant tumors
- Detection of malignant tumors
- Selected types of malignant tumors

 Cancer is a group of diseases characterized by abnormal and uncontrolled cell growth with the potential to invade or spread to other parts of the body.






Cell cycle



Regulation of cell cycle


- Growth factors
- Cell cycle checkpoints



Terminology

- Cancer
- Oncology
- Neoplasm
 - Benign
 - Malignant
- Neoplasia

| CHARACTERISTICS | BENIGN | MALIGNANT |
|----------------------|--|---|
| Cell characteristics | Well-differentiated cells that resemble cells in the tissue of origin | Cells are undifferentiated, with anaplasia and atypical structure that often bears little resemblance to cells in the tissue of origin |
| Rate of growth | Usually progressive and slow; may come to a standstill or regress | Variable and depends on level of differentiation; the more undifferentiated the cells, the more rapid the rate of growth |
| Mode of growth | Grows by expansion without invading the surrounding tissues; usually encapsulated | Grows by invasion, sending out processes that infiltrate the surrounding tissues |
| Metastasis | Does not spread by metastasis | Gains access to blood and lymph channels to metastasize to other areas of the body |



Terminology

Cancer

<u>oma</u>


- Oncology
- Neoplasm
 - Benign
 - Malignant
 - Solid cancers
 - > Hematological cancers
- Neoplasia

Cancer


| TISSUE TYPE | BENIGN TUMORS | MALIGNANT TUMORS | |
|---------------|--|--|--|
| Epithelial | | | |
| Surface | Papilloma | Squamous cell carcinoma | |
| Glandular | Adenoma | Adenocarcinoma | |
| Connective | | 110 | |
| Fibrous | Fibroma | Fibrosarcoma | |
| Adipose | Lipoma | Liposarcoma | |
| Cartilage | Chondroma | Chondrosarcoma | |
| Bone | Osteoma | Osteosarcoma | |
| Blood vessels | Hemangioma | Hemangiosarcoma | |
| Lymph vessels | Lymphangioma | Lymphangiosarcoma | |
| Lymph tissue | 2. 72 - 73 | Lymphosarcoma | |
| Muscle | | | |
| Smooth | Leiomyoma | Leiomyosarcoma | |
| Striated | Rhabdomyoma | Rhabdomyosarcoma | |
| Neural Tissue | | | |
| Nerve cell | Neuroma | Neuroblastoma | |
| Glial tissue | Glioma | Glioblastoma, astrocytoma, medullobla oligodendroglioma | |
| Nerve sheaths | Neurilemmoma | Neurilemmal sarcoma | |
| Meninges | Meningioma | Meningeal sarcoma | |
| Hematologic | and the state of t | A CONTRACTOR OF THE PROPERTY O | |
| Granulocytic | | Myelocytic leukemia | |
| Erythrocytic | | Erythrocytic leukemia | |
| Plasma cells | | Multiple myeloma | |
| Lymphocytic | | Lymphocytic leukemia or lymphoma | |


Pathogenesis

Carcinogenesis



Infiltration, invasion and metastasis





Causes and risk factors



Staging and grading of cancer

- Grading: I-IV
- Staging: American Joint Committee on Cancer (AJCC)
- TNM
 - T stands for the size and local spread of the primary tumor (0-4)
 - N refers to the involvement of the regional lymph nodes (0-3)
 - M describes the extent of the metastatic involvement (0-1)

T2N1M0 indicates a moderate-size tumor with limited lymph nodal disease and no metastasis


Diagnosis


- Tumor markers (biomarkers)
- Cytological and histological methods
 - Tissue biopsy
 - Immunohistochemistry
 - Microarray technology
- Ultrasonography
- Computed tomography (CT)
- Magnetic resonance imaging (MRI)

| TABLE 8.5 TUMOR MARKE | RS | ** |
|---|---|---|
| MARKER | SOURCE | ASSOCIATED CANCERS |
| Antigens | | |
| AFP | Fetal yolk sac and gastrointestinal structures early in fetal life | Primary liver cancers; germ cell cancer of the testis |
| CA 15-3 | Breast tissue protein | Tumor marker for tracking breast cancer; liver, lung |
| CA 27.29 | Breast tissue protein | Breast cancer recurrence and metastasis |
| CEA | Embryonic tissues in gut, pancreas, liver, and breast | Colorectal cancer and cancers of the pancreas, lung, and stomach |
| Hormones | | |
| hCG | Hormone normally produced by placenta | Gestational trophoblastic tumors; germ cell cancer of testis |
| Calcitonin | Hormone produced by thyroid parafollicular cells | Thyroid cancer |
| Catecholamines (epinephrine, norepinephrine) and metabolites | Hormones produced by chromaffin cells of the adrenal gland | Pheochromocytoma and related tumors |
| Specific Proteins | | |
| Monoclonal immunoglobulin | Abnormal immunoglobulin produced by neoplastic cells | Multiple myeloma |
| PSA | Produced by the epithelial cells lining the acini and ducts of the prostate | Prostate cancer |
| Mucins and Other Glycoproteins | | |
| CA-125 | Produced by müllerian cells of ovary | Ovarian cancer |
| CA-19-9 | Produced by alimentary tract epithelium | Cancer of the pancreas, colon |
| Cluster of Differentiation | | |
| CD antigens | Present on leukocytes | Used to determine the type and level of differentiation of leukocytes involved in different types of leukemia and lymphom |


Breast cancer

Definition







- Ductal carcinoma
- Lobular carcinoma
- 1. Ductal carcinoma in situ (DCIS)



- Ductal carcinoma
- Lobular carcinoma
- 2. Lobular carcinoma in situ (LCIS)




- Ductal carcinoma
- Lobular carcinoma
- 3. Invasive ductal carcinoma (IDC)



Breast cancer

- Ductal carcinoma
- Lobular carcinoma
- 4. Invasive lobular carcinoma (ILC)

Solid Cancer



- Ductal carcinoma
- Lobular carcinoma
- 5. Inflammatory breast cancer (IBC)
- 6. Triple-negative breast cancer (TNBC)

Breast cancer

Risk factors

- Age and gender
- Family history
- Personal history of breast cancer
- Menstrual cycle
- Childbirth
- Hormone replacement therapy (HRT) or oral contraceptives
- Obesity
- Radiation
- Benign breast tumor

Breast cancer

Symptoms

- Painless (when present deeply, painful superficially), hard mass that has irregular edges, but sometimes it can be soft, and rounded.
- Swelling of all or part of the breast
- Skin dimpling
- Breast or nipple pain
- Nipple retraction (turning inward)
- Redness, or thickening of the nipple or breast skin
- Nipple discharge (may be bloody, clear to yellow, green and look like pus)
- Skin ulcers
- Swelling of one arm (beside the breast with cancer)

Malignant breast tumors

Staging

- a. Stage 0
- b. Stage 1
- c. Stage 2
- d. Stage 3
- e. Stage 4

Breast cancer

Diagnosis


- Breast self-exam (BSE)
- Clinical breast exam (CBE)
- Mammography
- Breast ultrasound (sonography)
- Magnetic resonance imaging (MRI)
- Biopsy
 - Excisional biopsy
 - Incisional biopsy
 - Core biopsy
 - Fine-needle aspiration (FNA) biopsy
- Immunohistochemistry: Estrogen, progesterone, HER2 receptors
- Microarray
- Tumor markers: CA-15-3 and CA-27-29

Breast cancer

Treatment


- Surgery
 - Breast-conserving surgery
 - Lumpectomy
 - Partial mastectomy
 - Total mastectomy
 - Modified radical mastectomy
- Radiation therapy: external or internal
- Anticancer drugs
 - Chemotherapy, TAC: paclitaxel, doxorubicin (Adriamycin), and cyclophosphamide
 - Hormonal therapy: Tamoxifen and Aromatase inhibitors (Als)
 - Targeted therapy: Trastuzumab (monoclonal antibody of HER2)

- Definition
- Types




Leukemia

- Definition
- Types




Leukemia

Causes and risk factors



Leukemia


Symptoms




Anemia Fatigue

Leukemia

Diagnosis






Leukemia

- Treatment
- 1. Chemotherapy
 - a. Remission induction therapy
 - b. Consolidation therapy
 - c. Maintenance therapy
- 2. Radiation therapy
- 3. Hematopoietic stem cell transplantation (HSCT): autologous SCT (auto-SCT) and allogeneic SCT (allo-SCT)
- 4. Immunotherapy
- **5. Targeted therapy**


Lymphoma

- Definition
- Types
 - > Hodgkin lymphoma (HL)
 - ➤ Non-Hodgkin lymphoma (NHL)




Lymphoma


Symptoms



Lymphoma

Diagnosis





Lymphoma

- Treatment
- 1. Chemotherapy
- 2. Radiation therapy
- 3. Hematopoietic stem cell transplantation (HSCT): autologous SCT (auto-SCT) and allogeneic SCT (allo-SCT)
- 4. Immunotherapy
- 5. Targeted therapy